Dyne Therapeutics (NASDAQ:DYN – Free Report) had its price target boosted by Jefferies Financial Group from $36.00 to $42.00 in a research note released on Monday, Benzinga reports. Jefferies Financial Group currently has a buy rating on the stock. DYN has been the topic of several other research reports. Morgan Stanley assumed coverage on Dyne […]
Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) had its price target increased by research analysts at Canaccord Genuity Group from $6.00 to $8.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective would suggest a potential […]
Outlook Therapeutics, Inc. (NASDAQ:OTLK – Free Report) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Outlook Therapeutics in a research report issued to clients and investors on Friday, May 17th. HC Wainwright analyst D. Tsao expects that the company will post earnings per share of ($1.00) for the quarter. HC […]
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) has been assigned a consensus rating of “Hold” from the five research firms that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price […]
Summit Therapeutics Inc. (NASDAQ:SMMT – Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed at $4.39, but opened at $4.50. Summit Therapeutics shares last traded at $4.39, with a volume of 51,424 shares changing hands. Analysts Set New Price Targets A number of equities research analysts have recently […]